Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1947 9
1948 4
1949 1
1950 3
1951 5
1952 5
1953 3
1954 3
1955 9
1956 10
1957 15
1958 34
1959 52
1960 49
1961 30
1962 68
1963 126
1964 121
1965 100
1966 70
1967 111
1968 121
1969 149
1970 183
1971 166
1972 183
1973 200
1974 193
1975 200
1976 190
1977 236
1978 224
1979 222
1980 215
1981 228
1982 232
1983 237
1984 249
1985 258
1986 268
1987 251
1988 312
1989 371
1990 375
1991 401
1992 423
1993 446
1994 493
1995 511
1996 532
1997 494
1998 543
1999 496
2000 513
2001 525
2002 610
2003 607
2004 557
2005 655
2006 717
2007 618
2008 704
2009 731
2010 723
2011 736
2012 788
2013 777
2014 868
2015 811
2016 776
2017 783
2018 832
2019 865
2020 930
2021 990
2022 957
2023 870
2024 269

Text availability

Article attribute

Article type

Publication date

Search Results

26,827 results

Results by year

Filters applied: . Clear all
Page 1
Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ. Hamill RJ. Drugs. 2013 Jun;73(9):919-34. doi: 10.1007/s40265-013-0069-4. Drugs. 2013. PMID: 23729001 Review.
In an attempt to improve the therapeutic index of amphotericin B, three lipid-associated formulations were developed, including amphotericin B lipid complex (ABLC), liposomal amphotericin B (L-AmB), and amphotericin B colloi …
In an attempt to improve the therapeutic index of amphotericin B, three lipid-associated formulations were developed, includin …
Amphotericin B.
Lemke A, Kiderlen AF, Kayser O. Lemke A, et al. Appl Microbiol Biotechnol. 2005 Aug;68(2):151-62. doi: 10.1007/s00253-005-1955-9. Epub 2005 Apr 9. Appl Microbiol Biotechnol. 2005. PMID: 15821914 Review.
In order to improve its safety margin, new pharmaceutical formulations of amphotericin B have been designed especially to reduce its detrimental effects on the kidneys. ...This review describes and discusses the molecular genetics, pharmacological, toxicological, an …
In order to improve its safety margin, new pharmaceutical formulations of amphotericin B have been designed especially to redu …
Amphotericin B nephrotoxicity.
Sabra R, Branch RA. Sabra R, et al. Drug Saf. 1990 Mar-Apr;5(2):94-108. doi: 10.2165/00002018-199005020-00003. Drug Saf. 1990. PMID: 2182052 Review.
The frequency of fungal infections is increasing. Amphotericin B remains the anti-fungal drug of choice for most systemic infections, but a limiting factor for its use is the development of nephrotoxicity. ...In the clinical situation, and in long term models of nep …
The frequency of fungal infections is increasing. Amphotericin B remains the anti-fungal drug of choice for most systemic infe …
Comparison between liposomal formulations of amphotericin B.
Adler-Moore JP, Gangneux JP, Pappas PG. Adler-Moore JP, et al. Med Mycol. 2016 Mar;54(3):223-31. doi: 10.1093/mmy/myv111. Epub 2016 Jan 14. Med Mycol. 2016. PMID: 26768369 Review.
Given the clinical success of commercial amphotericin B lipid products, investigators have begun making generic formulations of liposomal amphotericin B. ...This is of particular concern for liposomal drugs such as amphotericin B where li …
Given the clinical success of commercial amphotericin B lipid products, investigators have begun making generic formulations o …
Amphotericin B: an introduction.
Warnock DW. Warnock DW. J Antimicrob Chemother. 1991 Oct;28 Suppl B:27-38. doi: 10.1093/jac/28.suppl_b.27. J Antimicrob Chemother. 1991. PMID: 1778890 Review.
Amphotericin B has a broad spectrum of action that includes most of the major fungal pathogens of man. ...Interactions between amphotericin B and a number of other antimicrobial drugs have been observed in tests in vitro and in vivo. ...
Amphotericin B has a broad spectrum of action that includes most of the major fungal pathogens of man. ...Interactions between …
Amphotericin B colloidal dispersion.
Patel R. Patel R. Expert Opin Pharmacother. 2000 Mar;1(3):475-88. doi: 10.1517/14656566.1.3.475. Expert Opin Pharmacother. 2000. PMID: 11249532 Review.
ABCD is associated with less nephrotoxicity than conventional amphotericin B deoxycholate. Infusion-related adverse events are more frequent in patients receiving ABCD than in patients receiving liposomal amphotericin B or amphotericin B …
ABCD is associated with less nephrotoxicity than conventional amphotericin B deoxycholate. Infusion-related adverse events are …
[Liposomal amphotericin B].
Fukasawa M. Fukasawa M. Nihon Ishinkin Gakkai Zasshi. 2005;46(4):229-31. doi: 10.3314/jjmm.46.229. Nihon Ishinkin Gakkai Zasshi. 2005. PMID: 16282964 Free article. Review. Japanese.
Liposomal amphotericin B (AmBisome) is a DDS (drug delivery system) formulation of amphotericin B (AMPH-B), and has been developed in an attempt to reduce the toxicity of AMPH-B while retaining its therapeutic efficacy. ...
Liposomal amphotericin B (AmBisome) is a DDS (drug delivery system) formulation of amphotericin B (AMPH-B), and …
Safe and Effective Delivery of Amphotericin B: A Survey of Patents.
Kaur L, Abhijeet, Jain SK. Kaur L, et al. Recent Pat Nanotechnol. 2017;11(3):214-234. doi: 10.2174/1872210511666170105130210. Recent Pat Nanotechnol. 2017. PMID: 28056751 Review.
METHOD: The patent search on "Amphotericin B for its safe and effective delivery" has been carried out to present assimilated information on the patents of the universally accepted Amphotericin B formulations and technologies. Also, the area of focus w …
METHOD: The patent search on "Amphotericin B for its safe and effective delivery" has been carried out to present assimilated …
Liposomal amphotericin B, AmBisome.
Hay RJ. Hay RJ. J Infect. 1994 May;28 Suppl 1:35-43. doi: 10.1016/s0163-4453(94)95956-0. J Infect. 1994. PMID: 8077689 Review.
The unilamellar liposomal formulation of amphotericin B, AmBisome, is composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol and cholesterol. ...AmBisome has been used in two open studies of patients with invasive aspergillosis; in one of …
The unilamellar liposomal formulation of amphotericin B, AmBisome, is composed of hydrogenated soy phosphatidylcholine, distea …
Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections?
Nagata MP, Gentry CA, Hampton EM. Nagata MP, et al. Ann Pharmacother. 1996 Jul-Aug;30(7-8):811-8. doi: 10.1177/106002809603000720. Ann Pharmacother. 1996. PMID: 8826566 Review.
Additional references were obtained from the articles retrieved from MEDLINE. STUDY SELECTION: Studies that directly assessed amphotericin B dosage and/or duration, pharmacokinetic literature dealing with plasma concentrations and amphotericin B dispos …
Additional references were obtained from the articles retrieved from MEDLINE. STUDY SELECTION: Studies that directly assessed amphoterici …
26,827 results
You have reached the last available page of results. Please see the User Guide for more information.